Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zogenix To Pay $250m Upfront To Buy Modis For Ultra-Orphan Drug

Executive Summary

The takeover will diversify Zogenix’s pipeline through the addition of MT1621, a drug that improved the probability of survival in patients with an inherited mitochondrial DNA depletion disorder.

You may also be interested in...



Deal Watch: BMS To Tap Early-Stage Breakthroughs In Partnership With BioMotiv

Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.

Who’s Hired? O’Brien To Replace Richards As Mayne Pharma CEO

Mayne Pharma has announced the appointment of pharma industry veteran Shawn O’Brien as CEO, replacing outgoing delegate Scott Richards. Plus, Hikma has appointed two new female board members, in line with gender diversity targets set by the UK Financial Conduct Authority.

MagGenome On Path To Nanoparticle Adjuvant, Founder Seeks Investment Opportunities

MagGenome, an Indian biotech which develops nanoparticle-based products, is in the early stage of research for a vaccine adjuvant. Scrip spoke to founder Sam Santhosh and CEO and chief scientific officer C N Ramchand to gauge the promise of nanotechnology and the environment in India for cell and gene therapies, among other topics, in this wide-ranging audio interview. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel